UBRELVY® works
UBRELVY is the first acute treatment for migraine to directly block CGRP1
Calcitonin gene-related peptide (CGRP) is a neurotransmitter that plays a major role in migraine attacks.2,3 When released, it attaches to CGRP receptors causing pain, inflammation, and vasodilation.2-4 Unlike other agents that work on the presynaptic serotonin receptor,* UBRELVY targets the receptors postsynaptically and blocks CGRP proteins.3,5
During a migraine attack:
CGRP is released and attaches to CGRP receptors, causing pain signaling.2-4
During a migraine attack:
CGRP is released and attaches to CGRP receptors, causing pain signaling.2-4
UBRELVY works differently:
UBRELVY stops CGRP proteins from reaching the postsynaptic neurons, thereby blocking migraine pain signaling.3
UBRELVY works differently:
UBRELVY stops CGRP proteins from reaching the postsynaptic neurons, thereby blocking migraine pain signaling.3
*Triptans are agonists that bind to presynaptic serotonin receptors (5-HT1B or 5-HT1D), constricting blood vessels and preventing release of additional neuropeptides, including CGRP. Those that have already been released continue to circulate.2-4
UBRELVY works in many ways to strike down to zero migraine pain5,6
UBRELVY pharmacokinetic characteristics
UBRELVY is an immediate-release tablet that is rapidly dissolved and pharmacologically active within minutes6-8
Pharmacokinetic profile
9 to 11 minutes: time to pharmacologically active concentration with UBRELVY 100 mg and UBRELVY 50 mg, respectively6,7†
Tmax: 1.5 hours to peak plasma concentrations5
Half-life: 5 to 7 hours to elimination5
The clinical significance of these data is not known.
UBRELVY displays dose-proportional pharmacokinetics within the recommended dose range.5
†Time to pharmacologically active concentration with UBRELVY 50 mg based on the inhibition of human capsaicin-induced dermal vasodilation model, a pharmacodynamic measure of CGRP blockade, EC90=13 ng/mL.7
Up next: Help enable access to UBRELVY